390 related articles for article (PubMed ID: 33162515)
21. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
22. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
23. Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.
Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2020 Nov; 13(11):1189-1199. PubMed ID: 33076714
[TBL] [Abstract][Full Text] [Related]
24. Management of hydroxyurea resistant or intolerant polycythemia vera.
Raman I; Pasricha SR; Prince HM; Yannakou CK
Leuk Lymphoma; 2021 Oct; 62(10):2310-2319. PubMed ID: 33949918
[TBL] [Abstract][Full Text] [Related]
25. Can pegylated interferon improve the outcome of polycythemia vera patients?
Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
[TBL] [Abstract][Full Text] [Related]
26. Moving toward disease modification in polycythemia vera.
Bewersdorf JP; How J; Masarova L; Bose P; Pemmaraju N; Mascarenhas J; Rampal RK
Blood; 2023 Nov; 142(22):1859-1870. PubMed ID: 37729609
[TBL] [Abstract][Full Text] [Related]
27. Givinostat: an emerging treatment for polycythemia vera.
Chifotides HT; Bose P; Verstovsek S
Expert Opin Investig Drugs; 2020 Jun; 29(6):525-536. PubMed ID: 32693648
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
[TBL] [Abstract][Full Text] [Related]
30. Management of polycythaemia vera: a critical review of current data.
McMullin MF; Wilkins BS; Harrison CN
Br J Haematol; 2016 Feb; 172(3):337-49. PubMed ID: 26492433
[TBL] [Abstract][Full Text] [Related]
31. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
Finazzi G; Barbui T
Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
[TBL] [Abstract][Full Text] [Related]
32. [State-of-the-art management for essential thrombocythemia and polycythemia vera].
Sugimoto Y
Rinsho Ketsueki; 2021; 62(8):1050-1059. PubMed ID: 34497191
[TBL] [Abstract][Full Text] [Related]
33. Polycythemia vera: current pharmacotherapy and future directions.
Hensley B; Geyer H; Mesa R
Expert Opin Pharmacother; 2013 Apr; 14(5):609-17. PubMed ID: 23480062
[TBL] [Abstract][Full Text] [Related]
34. Thromboembolic events in polycythemia vera.
Griesshammer M; Kiladjian JJ; Besses C
Ann Hematol; 2019 May; 98(5):1071-1082. PubMed ID: 30848334
[TBL] [Abstract][Full Text] [Related]
35. Ruxolitinib in a Child With JAK2 Exon 12 Mutant Polycythemia Vera.
Stoops K; Kuril S
J Pediatr Hematol Oncol; 2023 May; 45(4):e502-e505. PubMed ID: 36161965
[TBL] [Abstract][Full Text] [Related]
36. Treatment of polycythemia vera.
Dulíček P
Vnitr Lek; 2018; 64(10):955-960. PubMed ID: 30590943
[TBL] [Abstract][Full Text] [Related]
37. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
38. Current and future treatment options for polycythemia vera.
Griesshammer M; Gisslinger H; Mesa R
Ann Hematol; 2015 Jun; 94(6):901-10. PubMed ID: 25832853
[TBL] [Abstract][Full Text] [Related]
39. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
